Research programme: BACE1 protein inhibitors - Pfizer

Drug Profile

Research programme: BACE1 protein inhibitors - Pfizer

Alternative Names: WAC-547415; WAY-258131; WY-24454

Latest Information Update: 03 Sep 2010

Price : $50

At a glance

  • Originator Wyeth
  • Developer Pfizer
  • Class Fluorobenzenes; Hydantoins; Imidazoles; Pyridines; Small molecules
  • Mechanism of Action BACE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 26 Aug 2010 Pharmacodynamics data from preclinical trials in Alzheimer's disease presented at the 240th American Chemical Society National Meeting (ACS-2010)
  • 15 Oct 2009 Wyeth has been acquired by Pfizer
  • 20 Aug 2009 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top